scorecardresearch
Monday, July 21, 2025
TopicDilip Shanghvi

Topic: Dilip Shanghvi

Sun Pharmaceuticals undergoes SEBI-ordered forensic audit

The latest probe points to challenges for India’s biggest drugmaker after whistle-blower complaints on corporate governance lapses triggered a stock slide last year.

Dilip Shanghvi of Sun Pharmaceutical’s to keep stake in Suzlon Energy despite falling value

In 2015, billionaire Dilip Shanghvi bought 23% stake for Rs 18 billion, but Suzlon still hasn’t exited India’s debt-restructuring program, missing deadlines since 2017.

On Camera

India’s TRP ecosystem needs a reset. Time to end BARC monopoly

A ratings monopoly in India has led to lack of technological variation, resulting in sluggish systems detached from market dynamics.

India-US set to ink mini trade deal soon, reach understanding on agricultural & dairy products

Mini deal will likely see no cut in 10% baseline tariff on Indian exports announced by Trump on 2 April, it is learnt, but additional 26% tariffs are set to be reduced.

Not just AK-203, India & Russia to jointly manufacture AK-19 and PPK-20 for domestic use and export 

India-Russia JV is also racing to deliver 7,000 more AK-203 assault rifles by 15 Aug. These are currently being made with 50% indigenisation and this will surge to 100% by 31 December.

Strategic partner one day, tactical nightmare the next: India’s learning Trumplomacy the hard way

Public, loud, upfront, filled with impropriety and high praise sometimes laced with insults. This is what we call Trumplomacy. But the larger objective is the same: American supremacy.